22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Localization of myocardial scar in patients with cardiomyopathy and left bundle branch block using electrocardiographic Selvester QRS scoring - comparison with cardiac magnetic resonance

      abstract

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background The left ventricular (LV) lead in cardiac resynchronization therapy (CRT) can be placed on any non-septal LV wall, most commonly the lateral wall. Presence of myocardial scar adversely affects CRT outcome, particularly if it involves the LV pacing site. It is increasingly important to identify and localize myocardial scar in CRT candidates, the majority of whom have left bundle branch block (LBBB). We aimed to describe the diagnostic performance of electrocardiographic (ECG) criteria based on the Selvester QRS score in localizing myocardial scar into 5 LV wall segments and in detecting non-septal scar in patients with LBBB using Cardiac Magnetic Resonance as the gold standard. Methods In 39 cardiomyopathy patients with strictly defined LBBB (17 with scar, 22 without scar), late gadolinium enhancement cardiac magnetic resonance images (CMR-LGE) and 12-lead ECGs were analyzed for scar presence in 5 LV wall segments. Using stepwise regression analysis, multiple subsets of the Selvester QRS score ECG criteria were identified for each of the 5 individual segments and for the 4 non-septal segments together. The diagnostic performance of each of these subsets is displayed in the graph below. The one subset for each location that had the highest combination of sensitivity plus specificity was selected. Results The best identified subset of Selvester QRS score criteria for screening of non-septal scar had 75% (95% CI: 51-90%) sensitivity, 95% (78-99%) specificity, 92% (67-99%) positive predictive value and 84% (65-94%) negative predictive value. For each individual wall segment, 40-60% sensitivities and 77-100% specificities were found. Conclusions The 12-lead ECG can convey information about scar presence and location in patients with cardiomyopathy and LBBB. ECG screening criteria for scar in potential CRT LV pacing sites were identified. Further exploration is required to determine the clinical utility of the 12-lead ECG in combination with other imaging modalities to screen for scar in potential LV pacing sites in CRT candidates. Funding The study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health (HL103812 to KCW, HL91062 to GFT, and HL61912 to RGW), the DW Reynolds Foundation and the FDA Critical Path Initiative. Figure 1 This sensitivity vs 1-specificity graph displays the diagnostic performances of all the subsets of the Selvester QRS score ECG criteria that were identified in detecting myocardial scar in each of the five LV wall segments, as well as in the four non-septal segments together.

          Related collections

          Author and article information

          Conference
          J Cardiovasc Magn Reson
          J Cardiovasc Magn Reson
          Journal of Cardiovascular Magnetic Resonance
          BioMed Central
          1097-6647
          1532-429X
          2013
          30 January 2013
          : 15
          : Suppl 1
          : P61
          Affiliations
          [1 ]Clinical physiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
          [2 ]Division of cardiology, department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA
          [3 ]School of Medicine, Duke University, Durham, NC, USA
          [4 ]Duke Clinical Research Institute, Duke University, Durham, NC, USA
          [5 ]Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, MD, USA
          Article
          1532-429X-15-S1-P61
          10.1186/1532-429X-15-S1-P61
          3559999
          702afd3c-d228-4eb8-a43f-b2e0714a66fd
          Copyright ©2013 Wieslander et al; licensee BioMed Central Ltd.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

          16th Annual SCMR Scientific Sessions
          San Francisco, CA, USA
          31 January-3 February 2013
          History
          Categories
          Poster Presentation

          Cardiovascular Medicine
          Cardiovascular Medicine

          Comments

          Comment on this article